0.40Open0.40Pre Close0 Volume370 Open Interest30.00Strike Price0.00Turnover133.98%IV15.69%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type-0.1359Delta0.0402Gamma87.78Leverage Ratio-0.1206Theta-0.0007Rho-11.93Eff Leverage0.0088Vega
Ultragenyx Pharmaceutical Stock Discussion
Breakthrough: Ultragenyx's Gene Therapy Reverses Cognitive Decline in Fatal Childhood Disease
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that the European Commission has extended the approval of Evkeeza® (evinacumab) to treat children aged 6-months and older with homozygous familial hypercholesterolemia (HoFH). Evkeeza is the first medicine in the EU approved f...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$